BLOG

pharma shots

James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs

Our lead anti-infective candidate, RECCE® 327 (R327), will be advancing into a Phase Ia/IIb intravenous multiple ascending dose safety and tolerability study and a Phase II clinical trial investigating the efficacy of R327 against diabetic foot ulcer (DFU) infections.